GO
Loading...

Enter multiple symbols separated by commas

Court Rules in Favor of Ariad in Eli Lilly Suit

Ariad Pharmaceuticals said a U.S. federal court ruled in favor of it and co-complainants in a patent infringement case against Eli Lilly, saying that the patent was valid and enforceable.

The patent covered methods of treating human disease by regulating NF-(kappa)B cell-signaling activity, the biotechnology company said in a statement.

Ariad has an exclusive license to patents related to certain NF-(kappa)B treatment methods, the company said.

In May 2006, a jury had ruled in favor of Ariad and other complainants saying the patent claims asserted in the lawsuit were valid and infringed with respect to Eli Lilly's osteoporosis drug, Evista, and septic shock drug, Xigris.

The jury had also awarded damages of about $65.2 million. The co-complainants are Massachusetts Institute of Technology, Whitehead Institute for Biomedical Research, and President and Fellows of Harvard College, Ariad said.

Ariad also said that the U.S. Patent and Trademark Office issued a final office action in its re-examination of the NF-(kappa)B patent.

The Patent and Trademark Office rejected the patentability of certain claims of the patent, including those asserted in the Eli Lilly lawsuit and a separate lawsuit against Amgen and Wyeth, Ariad said.

In April, Ariad said it had filed a counter claim against Amgen and Wyeth alleging patent infringement. The claim was in response to a lawsuit filed by Amgen seeking to invalidate claims of NF-(kappa)B patent, Ariad said.

Contact U.S. News

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    To learn more about how we use your information,
    please read our Privacy Policy.

Don't Miss

  • Ferrari 488 Spider

    Ferrari's new 488 Spider will have a V-8 turbo engine and a retractable hard-top roof that lowers in just 14 seconds.

  • FDA bans import of some Cilantro as annually recurring outbreaks (in 2012, 2013, and 2014) of cyclosporiasis in the United States which have been associated with fresh cilantro from the state of Puebla, Mexico.

    The FDA announced the partial ban after some cilantro was linked to 2013 and 2014 outbreaks of stomach illnesses in the US.

  • Thomas Lee

    This year's flat market is reminiscent of 1904, says Thomas Lee of Fundstrat Global Advisors in an interview with Amanda Drury.

U.S. Video

  • CNBC update: NFL upholds Tom Brady's suspension

    Representatives from 70 countries are meeting in Spain on counter-terrorism strategies, and NFL Commissioner Roger Goodell has upheld the 4 game suspension of Tom Brady, reports CNBC's Sue Herera.

  • China markets historically wild: Pro

    Insight to the action in China's stock market, and buildup of debt in the economy there, with Ken Brown, Wall Street Journal Asia Finance Editor & Hong Kong Bureau Chief.

  • And America's best burger goes to...

    CNBC's Jane Wells takes a bite out of the top five burgers in America according to The Daily Meal.